An Epidemiologic-Based Survey of Public Attitudes Towards Predictive Genetic Testing in Russia

Makeeva, O. A.; Markova, Valentina V.; Roses, Allen D.; Puzyrev, V. P.

doi:10.2217/pme.10.23

Cited by 27 publications

(33 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interest in genetic testing has been described, in particular also for multifactorial diseases in which the contribution of genes is rather low. 14,15,21 Increasing use of testing is thus expected, in particular with decreasing costs of testing. 14 We are now entering a new period in genetics as sequencing becomes cheaper and whole genome sequencing is being used in clinical care.…”

Section: Discussionmentioning

confidence: 99%

“…11 Attitudes towards genetic testing vary with age, gender and educational level. Overall, younger people seem to show a higher interest in genetic testing, [13][14][15] and have more positive attitudes. 13,16 Men seem to have more positive attitudes towards testing, 10,13 but some studies have indicated that women are more knowledgeable on genetics.…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

Public attitudes towards genetic testing revisited: comparing opinions between 2002 and 2010

et al. 2012

View full text Add to dashboard Cite

Ten years after the Human Genome Project, medicine is still waiting for many of the promised benefits, and experts have tempered their high expectations. Public opinion on genetic testing has generally been favourable but is this still the case? The aim of this study is to compare public experiences, beliefs and expectations concerning genetic testing over the years (2002 vs 2010). A cross-sectional questionnaire survey was conducted using the Dutch Health Care Consumer Panel in 2002 and 2010. Responses to questions in identical wording were compared. In 2002 and 2010, 817 (63%) and 978 (70%) members responded, respectively. Awareness and reported use of genetic tests remained stable over time. In 2010, more respondents expected genetic testing to become more widely applied, believed that knowledge about the genetic background of disease helps people live longer, and that testing should be promoted more intensively. In 2010, they were also more interested in their own genetic make-up. On the one hand, the concern that a dichotomy would emerge between people with 'good genes' and 'bad genes' was higher. On the other hand, respondents thought that insurance companies would be less likely to demand a genetic test in order to calculate health insurance premiums. In conclusion, the results suggest that in 8 years, expectations of benefits and potential use of genetic testing have been raised among the public, resulting in more positive opinions. Worries on inequity remain, although worries about premium differentiation by insurance companies have decreased.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

Public attitudes towards genetic testing revisited: comparing opinions between 2002 and 2010

et al. 2012

View full text Add to dashboard Cite

show abstract

“…However, limited evidence is available regarding the attitude of health professionals towards riboflavin as a targeted treatment option for BP management. In recent years, there is increasing public interest in genetic testing in the health field, in a study investigating attitudes to genetic testing among 2000 individuals, 81 % of respondents believed that knowing their genetic risk could lead to better control of their lives (108) . A number of studies have reported that individuals identified as having a higher disease risk through genetic testing may be more motivated to change dietary habits (109)(110)(111) .…”

Section: Mechanism Of Mthfr C677t Polymorphism Riboflavin and Blood mentioning

confidence: 99%

Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

et al. 2016

View full text Add to dashboard Cite

Clinical deficiency of the B-vitamin riboflavin (vitamin B 2 ) is largely confined to developing countries; however accumulating evidence indicates that suboptimal riboflavin status is a widespread problem across the developed world. Few international data are available on riboflavin status as measured by the functional biomarker, erythrocyte glutathione reductase activation coefficient, considered to be the gold standard index. One important role of riboflavin in the form of flavin dinucleotide is as a co-factor for the folate-metabolising enzyme methylenetetrahydrofolate reductase (MTHFR). Homozygosity for the common C677T polymorphism in MTHFR, affecting over 10 % of the UK and Irish populations and up to 32 % of other populations worldwide, has been associated with an increased risk of CVD, and more recently with hypertension. This review will explore available studies reporting riboflavin status worldwide, the interaction of riboflavin with the MTHFR C677T polymorphism and the potential role of riboflavin in personalised nutrition. Evidence is accumulating for a novel role of riboflavin as an important modulator of blood pressure (BP) specifically in individuals with the MTHFR 677TT genotype, with results from a number of recent randomised controlled trials demonstrating that riboflavin supplementation can significantly reduce systolic BP by 5-13 mmHg in these genetically at risk adults. Studies are however required to investigate the BP-lowering effect of riboflavin in different populations and in response to doses higher than 1·6 mg/d. Furthermore, work focusing on the translation of this research to health professionals and patients is also required.Riboflavin: Methylenetetrahydrofolate reductase: MTHFR C677T: Blood pressure:Personalised nutrition Riboflavin (vitamin B 2 ) is a water-soluble B-vitamin defined chemically as 7,8-dimethyl-10-1′-D-ribityl isoalloxazine. It acts as a precursor for FMN and FAD (1) . Clinical riboflavin deficiency is not generally considered to be a problem in the developed world but in recent years evidence has shown that sub-optimal status may be more widespread than generally perceived based on studies reporting the functional biomarker, erythrocyte glutathione reductase activation coefficient (EGRac) generally considered as the gold standard index of status. Few international data are however available based on EGRac and reports on riboflavin status are more commonly based solely on dietary intake data. Although riboflavin is required for numerous metabolic reactions its role (in the form of FAD) as a cofactor for the folatemetabolising enzyme, methylenetetrahydrofolate reductase (MTHFR) has recently received particular attention. Homozygosity (MTHFR 677TT genotype) for a common polymorphism in MTHFR, affecting over 10 % of the UK and Irish populations and up to 32 % of other populations worldwide (2) , has been associated with an increased risk of CVD (3) and more recently with hypertension (4) . Emerging evidence from intervention trials supports a novel role for riboflav...

show abstract

“…This situation implies that a number of different strategies should be employed to enhance the potential societal and individual benefits of genomic medicine, by obtaining a better understanding on of how the general public and healthcare professionals perceive genetic services and genetics in general and genetic services in particular. So far, very few studies have been undertaken in a handful of European populations, namely in Finland [4], Germany [5] and Russia [6]. Recently, we reported our findings from similar nationwide surveys in Greece, to evaluate the services provided and the operational principles of private genetic laboratories [7] as well as to ascertain the views of both physicians' and the general public's views on genetics and genetic testing services [8].…”

Section: Introductionmentioning

confidence: 96%

Ascertainment and Critical Assessment of the Views of the General Public and Healthcare Professionals on Nutrigenomics in Greece

Pavlidis¹,

Karamitri²,

Barakou³

et al. 2012

Personalized Medicine

View full text Add to dashboard Cite

Executive Summary There is an urgent need to critically assess the nutrigenomics field, particularly since the general public is often misinformed about the potential benefits of correlating an individual's genomic genetic profile with their nutritional status. In this article, we attempt to shed light on the views and perceptions of healthcare professionals and the general public in relation to nutrigenomics, to investigate how a healthcare professional might include genetic testing in routine health examinations and how the general public in Greece can might eventually come to view see positively the use application of nutrigenomics in a positive light.

show abstract

An Epidemiologic-Based Survey of Public Attitudes Towards Predictive Genetic Testing in Russia

Cited by 27 publications

References 40 publications

Public attitudes towards genetic testing revisited: comparing opinions between 2002 and 2010

Public attitudes towards genetic testing revisited: comparing opinions between 2002 and 2010

Riboflavin status, MTHFR genotype and blood pressure: current evidence and implications for personalised nutrition

Ascertainment and Critical Assessment of the Views of the General Public and Healthcare Professionals on Nutrigenomics in Greece

Contact Info

Product

Resources

About